- What is kidney cancer?
- Localised (Stages I–III) disease
- Advanced (Stage IV) disease
- Systemic treatments for metastatic clear cell RCC
Kidney cancer (renal cell cancer or RCC) accounts for 2–3% of all adult cancers and is the 7th and 9th most common cancer in men and women respectively. It is estimated that 209,000 new cases and 102,000 deaths due to all RCCs occur annually worldwide. RCCs can emerge spontaneously or may be associated with other diseases, such as the hereditary renal cancer syndromes. The overall incidence of renal cell cancer is rising, which is at least partially attributable to increased incidental detection due to widespread use of abdominal imaging technologies, such as CT and magnetic resonance imaging (MRI).
For more information about the different types of RCC and how they are differentiated, see RCC Subtypes.
To determine the degree of RCC advancement, cancers are staged using the TNM staging system. Stages I to III refer to localised disease and stage IV refers to advanced disease. 5-year survival rates for individuals with RCC are 96% for stage I disease, 82% for stage II, 64% for stage III and 23% for stage IV disease.
Available treatments for kidney cancer depend on the degree of advancement. Localised RCCs (confined to the kidney) can be cured with surgery; however, surgery for metastatic clear cell RCC cannot cure RCC but still offers some survival benefit. Surgical options for RCC include:
- Nephron-sparing surgery or partial nephrectomy (where only part of the kidney is removed);
- Radical nephrectomy (entire kidney is removed); or
- Thermal ablation (destroying the cancer cells by applying concentrated heat).
Surgery for RCC aims to remove as much of the cancer as possible while preserving as much kidney function as possible. Even in metastatic (spread to other parts of the body) disease, total or partial removal of a primary tumour or deposits may still improve survival. Performing a partial nephrectomy is usually possible if metastatic tumours are less than 4 cm in diameter.
Medical therapies for RCC are generally only used in metastatic or advanced disease, or where surgery is not possible. These include conventional cancer therapies such as interferon alpha (IFN-alpha) therapy and IL-2 therapy. Advanced RCC can also be effectively treated with relatively new types of drugs, such as:
- Multiple receptor tyrosine kinase (rtk) inhibitors, such as sunitinib (e.g. Sutent), sorafenib (e.g. Nexavar) and pazopanib (e.g. Votrient);
- Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus (e.g. Afinitor) and temsirolimus (e.g. Torisel); and
- Monoclonal antibody therapies, such as bevacizumab (e.g. Avastin).
Given early stage tumours are small and localised, surgery by partial nephrectomy is generally recommended. If a tumour cannot be removed by surgery, a radical nephrectomy (total removal of the kidney) is appropriate. If other significant illnesses are also present, surgery may not be able to be performed. Those tumours treated with thermal ablation have an increased likelihood of local recurrence (growing back in the same location) but may be useful for those people who cannot undergo surgery.
In Stage II and III disease, partial nephrectomy is generally not suitable and curative radical nephrectomy is preferred. If the tumour extends into nearby blood vessels, a radical nephrectomy is essential and clots may have formed within the vessels that also require removal.
20–30% of individuals with localised disease will relapse (the tumour will regrow), most of which occur within 3 years. Scientific research has demonstrated no advantage in the use of medications or radiotherapy after surgery for localised RCC disease.
Individuals with stage IV disease may benefit from surgery despite the degree of metastasis. Removing some of the tumour (cytoreductive nephrectomy) before drug therapy has also been shown to improve survival in some people.
The use of drug therapies for advanced RCC disease has been effective. This includes the use of drugs such as multiple receptor tyrosine kinase (rtk) inhibitors (sunitinib, sorafenib and pazopanib), mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus) and monoclonal antibody therapies (bevacizumab).
Guidelines for the treatment of kidney cancer recommend the use of these drugs as first-line therapy for metastatic RCC disease. In the event of that one of these therapies doesn’t work, an alternate drug can be given.
- Rini BI, CampbellSC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373 (9669): 1119-32. [Abstract]
- Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281(17): 1628-31. [Abstract]
- DeVita VT, Lawrence TS, Rosenberg SA. Cancer Principles and Practice of Oncology. (8th edition). Philadelphia: Lippincott Williams & Wilkins; 2008. [Book]
- FossaSD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol. 1982;8:340-342. 
- Motzer RJ, Agarwal N, Beard C, et al. NCCN Clinical Practice Guidelines in Oncology – Kidney Cancer[Online]. National Comprehensive Cancer Network. Available from:
- Kapoor A. Inhibition of mTOR in kidney cancer. Curr Oncol. 2009; 16 Suppl 1: S33-9. [Abstract | ]
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2): 125-34. [Abstract | ]
- Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24. [Abstract | ]
- Sternberg CN, DavisID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6): 1061-8. [Abstract | ]
- Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22): 2271-81. [Abstract | ]
- Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372(9637): 449-56. 
- Webster WS, Thompson, RH, Cheville JC, et al. Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. Urology. 2007;70:900. 
- Australian Medicines Handbook. Chapter 14 –Immunomodulators and antineoplastics [online]. AMH 2012 [cited 24th May 2012]. Available from:
- Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw. 2009; 7(6): 635-42; quiz 643. [Abstract | Full Text]
- Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2010; 10(3): 305-17. [Abstract]
- Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10(8): 757-63. [Abstract]
- Bukowski RM. Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res. 2011; 3: 273-85. [Abstract | Full Text]
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10; 27(20): 3312-8. [Abstract | Full Text]
- Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009; 115(16): 3618-30. [Abstract | Full Text]
- Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9; 372(9637): 449-56. [Abstract]
- Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605): 2103-11. [Abstract]
- Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005 Jan 25;(1): CD001425. [Abstract | Full Text]
- Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: A large open-label study in diverse community settings. Annals Oncol. 2011; 22(8): 1812-23. [Full text]
- Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol. 2012; 2: e13. [Full text]
- Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. Oncologist. 2011; 16(2): 14-22. [Full text]
- Ravaud, A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011; 16(2): 32-44. [Full text]
- McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer. 2009; 115(s10): 2298-2305. [Full text]
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.